Trial Profile
A Phase II, Open-Label Multicenter Trial of Panobinostat Monotherapy in Women With HER2-Negative Locally Recurrent or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Mar 2012 This trial has been recruiting in France and United Kingdom; and completed in Ireland as reported by European Clinical Trials Database record.
- 29 Mar 2012 Planned number of patients changed from 118 to 130 as reported by European Clinical Trials Database record.